Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $257.95 million. The enterprise value is $616.47 million.
| Market Cap | 257.95M |
| Enterprise Value | 616.47M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 63.38 million shares outstanding. The number of shares has increased by 2.05% in one year.
| Shares Outstanding | 63.38M |
| Shares Change (YoY) | +2.05% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 11.16% |
| Owned by Institutions (%) | 66.31% |
| Float | 23.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 27.17 |
| PS Ratio | 0.50 |
| Forward PS | 0.48 |
| PB Ratio | 1.49 |
| P/FCF Ratio | 32.40 |
| PEG Ratio | 2.14 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 77.23 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 2.27.
| Current Ratio | 1.53 |
| Quick Ratio | 0.91 |
| Debt / Equity | 2.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | 49.47 |
| Interest Coverage | -2.84 |
Financial Efficiency
Return on equity (ROE) is -86.50% and return on invested capital (ROIC) is -21.18%.
| Return on Equity (ROE) | -86.50% |
| Return on Assets (ROA) | -18.70% |
| Return on Capital (ROIC) | -21.18% |
| Revenue Per Employee | $528,191 |
| Profits Per Employee | -$161,062 |
| Employee Count | 970 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.09 |
Taxes
In the past 12 months, Bioventus has paid $85,000 in taxes.
| Income Tax | 85,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +311.50% in the last 52 weeks. The beta is 0.50, so Bioventus's price volatility has been lower than the market average.
| Beta (1Y) | 0.50 |
| 52-Week Price Change | +311.50% |
| 50-Day Moving Average | 4.93 |
| 200-Day Moving Average | 4.20 |
| Relative Strength Index (RSI) | 28.91 |
| Average Volume (30 Days) | 143,403 |
Short Selling Information
The latest short interest is 787,337, so 1.24% of the outstanding shares have been sold short.
| Short Interest | 787,337 |
| Short Previous Month | 808,244 |
| Short % of Shares Out | 1.24% |
| Short % of Float | 3.40% |
| Short Ratio (days to cover) | 5.67 |
Income Statement
In the last 12 months, Bioventus had revenue of $512.35 million and -$156.23 million in losses. Loss per share was -$2.49.
| Revenue | 512.35M |
| Gross Profit | 328.19M |
| Operating Income | -120.39M |
| Pretax Income | -156.15M |
| Net Income | -156.23M |
| EBITDA | -58.10M |
| EBIT | -115.47M |
| Loss Per Share | -$2.49 |
Balance Sheet
The company has $36.96 million in cash and $394.85 million in debt, giving a net cash position of -$357.88 million or -$5.65 per share.
| Cash & Cash Equivalents | 36.96M |
| Total Debt | 394.85M |
| Net Cash | -357.88M |
| Net Cash Per Share | -$5.65 |
| Equity / Book Value | 173.59M |
| Book Value Per Share | 2.74 |
| Working Capital | 92.50M |
Cash Flow
In the last 12 months, operating cash flow was $15.34 million and capital expenditures -$7.36 million, giving a free cash flow of $7.98 million.
| Operating Cash Flow | 15.34M |
| Capital Expenditures | -7.36M |
| Free Cash Flow | 7.98M |
| FCF Per Share | $0.13 |
Margins
Gross margin is 64.06%, with operating and profit margins of -23.50% and -30.49%.
| Gross Margin | 64.06% |
| Operating Margin | -23.50% |
| Pretax Margin | -30.48% |
| Profit Margin | -30.49% |
| EBITDA Margin | -11.34% |
| EBIT Margin | -22.54% |
| FCF Margin | 1.56% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.05% |
| Shareholder Yield | -2.05% |
| Earnings Yield | -60.42% |
| FCF Yield | 3.09% |
Analyst Forecast
The average price target for Bioventus is $8.00, which is 96.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 96.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 0.01 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.01 |
| Piotroski F-Score | 5 |